Sie Djohan - PT Kalbe Management Devel
PTKFF Stock | USD 0.09 0.00 0.00% |
Executive
Mr. Sie Djohan serves as Director of PT Kalbe Farma Tbk since June 5, 2017. He obtained a degree in Pharmacy from Universitas Indonesia in 1990. He started his career in Kalbe Group acting as Group Marketing Manager of PT Dankos Farma in 19962001, then acted as Assistant Director of Marketing of PT Dankos Farma in 20012006. In 20062007 he acted as Assistant Director of Business Development Management System, PT Kalbe Farma Tbk, and in year 2007 present he acts as Director of Business Development, Management System Regulatory Affairs of PT Kalbe Farma Tbk. since 2017.
Age | 56 |
Tenure | 7 years |
Phone | 62 21 4287 3888 |
Web | https://www.kalbe.co.id |
PT Kalbe Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1673 %, meaning that it generated $0.1673 on every $100 dollars invested by stockholders. PT Kalbe's management efficiency ratios could be used to measure how well PT Kalbe manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Pierre Chancel | Sanofi ADR | 67 | |
William Pao | Roche Holding Ltd | 51 | |
Adrian Kemp | AstraZeneca PLC ADR | N/A | |
Steven Baert | Novartis AG ADR | 45 | |
Rachel Stahler | Organon Co | 48 | |
Jennifer Halchak | Organon Co | N/A | |
Joseph Morrissey | Organon Co | 59 | |
Paul Arkel | Novartis AG ADR | N/A | |
Shannon Klinger | Novartis AG ADR | 49 | |
Daniel Karp | Organon Co | 46 | |
Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
Brian McNamara | Novartis AG ADR | 47 | |
Geralyn Ritter | Organon Co | 55 | |
Susan MD | AstraZeneca PLC ADR | 58 | |
Sandra Esq | Bristol Myers Squibb | 63 | |
Charles Sawyers | Novartis AG ADR | 62 | |
Cristina Wilbur | Roche Holding Ltd | 56 | |
Samit MD | Bristol Myers Squibb | 55 | |
Michele Galen | Novartis AG ADR | N/A | |
Peter Kornicker | Novartis AG ADR | N/A | |
Jeffrey George | Novartis AG ADR | 41 |
Management Performance
Return On Equity | 0.17 | |||
Return On Asset | 0.11 |
PT Kalbe Farma Leadership Team
Elected by the shareholders, the PT Kalbe's board of directors comprises two types of representatives: PT Kalbe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTKFF. The board's role is to monitor PT Kalbe's management team and ensure that shareholders' interests are well served. PT Kalbe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PT Kalbe's outside directors are responsible for providing unbiased perspectives on the board's policies.
Djonny Tjahyadi, Director | ||
Lanny Soputro, G HR | ||
Ferdinand Aryanto, Commissioner | ||
Santoso Oen, Commissioner | ||
Ongkie Tedjasurja, Director | ||
Sie Djohan, Management Devel | ||
Bernadus Winata, Independent Director, Corporate Secretary | ||
Johannes Setijono, President Commissioner | ||
Bujung Nugroho, Director | ||
Lucky Slamet, Independent Commissioner | ||
Farid Moeloek, Independent Commissioner | ||
Kurniawan Suhartono, Head Unit | ||
Bernadette Setiady, President Director | ||
Lilis Halim, Independent Commissioner | ||
Bapak Vidjongtius, Corporate Secretary, Independent Director, Chairman of Good Corporate Governance Committee and Member of Bus. Risk Committee | ||
Johanes Ibrahim, Independent Commissioner | ||
Ronny Hadiana, Commissioner | ||
Lukito Gozali, Head Relations |
PTKFF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PT Kalbe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.17 | |||
Return On Asset | 0.11 | |||
Profit Margin | 0.12 % | |||
Current Valuation | 6.11 B | |||
Shares Outstanding | 46.26 B | |||
Shares Owned By Insiders | 58.08 % | |||
Shares Owned By Institutions | 15.23 % | |||
Price To Book | 5.15 X | |||
Price To Sales | 3.56 X | |||
Revenue | 26.26 T |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PT Kalbe Farma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PT Kalbe Farma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the PT Kalbe Farma information on this page should be used as a complementary analysis to other PT Kalbe's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for PTKFF Pink Sheet analysis
When running PT Kalbe's price analysis, check to measure PT Kalbe's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PT Kalbe is operating at the current time. Most of PT Kalbe's value examination focuses on studying past and present price action to predict the probability of PT Kalbe's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PT Kalbe's price. Additionally, you may evaluate how the addition of PT Kalbe to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |